iX Biopharma Past Earnings Performance

Past criteria checks 0/6

iX Biopharma has been growing earnings at an average annual rate of 2.3%, while the Pharmaceuticals industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 29.2% per year.

Key information

2.3%

Earnings growth rate

7.5%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate29.2%
Return on equity-248.7%
Net Margin-181.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How iX Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

Catalist:42C Revenue, expenses and earnings (SGD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 246-1172
31 Mar 246-1072
31 Dec 236-1072
30 Sep 236-1082
30 Jun 236-1093
31 Mar 235-1393
31 Dec 224-1693
30 Sep 229-1093
30 Jun 2214-592
31 Mar 2214-3102
31 Dec 2114-2103
30 Sep 218-593
30 Jun 212-883
31 Mar 212-883
31 Dec 202-883
30 Sep 201-982
30 Jun 201-1082
31 Mar 201-1283
31 Dec 191-1283
30 Sep 191-1383
30 Jun 191-1384
31 Mar 191-1486
31 Dec 180-1687
30 Sep 18-1-1578
30 Jun 180-1578
31 Mar 182-1486
31 Dec 173-1386
30 Sep 177-1086
30 Jun 176-785
31 Mar 176-475
31 Dec 166-475
30 Sep 166-666
30 Jun 166-876
31 Mar 166-1165
31 Dec 157-1165
30 Sep 157-1165
30 Jun 157-1165
31 Mar 156-853
31 Dec 145-643
30 Sep 143-432
30 Jun 142-321

Quality Earnings: 42C is currently unprofitable.

Growing Profit Margin: 42C is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 42C is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare 42C's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 42C is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.2%).


Return on Equity

High ROE: 42C has a negative Return on Equity (-248.71%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 03:14
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

iX Biopharma Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lee Keng LingDBS Bank Ltd
Paul ChewPhillip Securities Pte Ltd
Wee Kuang TayPhillip Securities Pte Ltd